- Home
- NIVF vs ENTO Comparison
NIVF vs ENTO Comparison
Compare NIVF & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- ENTO
- Stock Information
- Founded
- NIVF 2011
- ENTO 2014
- Country
- NIVF Hong Kong
- ENTO United States
- Employees
- NIVF N/A
- ENTO N/A
- Industry
- NIVF
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- ENTO Health Care
- Exchange
- NIVF NYSE
- ENTO Nasdaq
- Market Cap
- NIVF 2.1M
- ENTO 1.7M
- IPO Year
- NIVF N/A
- ENTO 2016
- Fundamental
- Price
- NIVF $2.95
- ENTO $0.42
- Analyst Decision
- NIVF
- ENTO
- Analyst Count
- NIVF 0
- ENTO 0
- Target Price
- NIVF N/A
- ENTO N/A
- AVG Volume (30 Days)
- NIVF 509.7K
- ENTO 131.6K
- Earning Date
- NIVF 01-01-0001
- ENTO 05-15-2025
- Dividend Yield
- NIVF N/A
- ENTO N/A
- EPS Growth
- NIVF N/A
- ENTO N/A
- EPS
- NIVF N/A
- ENTO N/A
- Revenue
- NIVF $5,433,375.00
- ENTO N/A
- Revenue This Year
- NIVF N/A
- ENTO N/A
- Revenue Next Year
- NIVF N/A
- ENTO N/A
- P/E Ratio
- NIVF N/A
- ENTO N/A
- Revenue Growth
- NIVF 5.79
- ENTO N/A
- 52 Week Low
- NIVF $1.09
- ENTO $0.19
- 52 Week High
- NIVF $32.80
- ENTO $3.16
- Technical
- Relative Strength Index (RSI)
- NIVF 37.46
- ENTO 54.54
- Support Level
- NIVF $2.80
- ENTO $0.37
- Resistance Level
- NIVF $3.77
- ENTO $0.44
- Average True Range (ATR)
- NIVF 0.74
- ENTO 0.04
- MACD
- NIVF 0.22
- ENTO 0.01
- Stochastic Oscillator
- NIVF 15.55
- ENTO 47.58
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.